Canopus Biopharma (CBIA) is showing potential for a bullish trajectory over the next 1-2 weeks, contingent on upcoming updates. The first target lies at the confluence area of the first trend line and Fibonacci ratio resistance around .0006. If this level is breached, the next target is at .0010.
Above these levels, I'll set my personal sell limit on 75% of my shares between .0019 - .0024. It's worth noting that penny stocks like CBIA are inherently risky, and I typically avoid them. Make sure to conduct your own due diligence and only enter trades if you're fully comfortable and aware of the risks involved. This analysis is for educational purposes only and not a recommendation to trade.
Above these levels, I'll set my personal sell limit on 75% of my shares between .0019 - .0024. It's worth noting that penny stocks like CBIA are inherently risky, and I typically avoid them. Make sure to conduct your own due diligence and only enter trades if you're fully comfortable and aware of the risks involved. This analysis is for educational purposes only and not a recommendation to trade.